MediWound Ltd. (NASDAQ:MDWD - Get Free Report)'s stock price passed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $17.29 and traded as low as $17.20. MediWound shares last traded at $17.70, with a volume of 21,690 shares.
Analyst Ratings Changes
Separately, HC Wainwright dropped their price objective on shares of MediWound from $28.00 to $25.00 and set a "buy" rating for the company in a report on Wednesday, November 27th.
Get Our Latest Analysis on MediWound
MediWound Trading Down 0.7 %
The firm has a market capitalization of $190.91 million, a P/E ratio of -6.10 and a beta of 0.81. The company has a 50-day moving average of $17.29 and a 200-day moving average of $17.46.
MediWound (NASDAQ:MDWD - Get Free Report) last issued its quarterly earnings data on Tuesday, November 26th. The biopharmaceutical company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.50). MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same period in the prior year, the company earned ($0.24) EPS. Research analysts predict that MediWound Ltd. will post -2.6 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in MDWD. MetLife Investment Management LLC bought a new stake in MediWound in the third quarter worth approximately $89,000. Rhumbline Advisers acquired a new stake in shares of MediWound during the 2nd quarter worth approximately $131,000. Barclays PLC increased its stake in shares of MediWound by 311.3% in the 3rd quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company's stock valued at $202,000 after acquiring an additional 8,449 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in shares of MediWound during the 3rd quarter valued at $212,000. Finally, Bank of New York Mellon Corp bought a new position in MediWound during the second quarter worth $342,000. 46.83% of the stock is owned by institutional investors and hedge funds.
MediWound Company Profile
(
Get Free Report)
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
See Also
Before you consider MediWound, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediWound wasn't on the list.
While MediWound currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
